Glucocorticoids, ocular hypertension and glaucoma

糖皮质激素、高眼压症和青光眼

基本信息

项目摘要

Glucocorticoids (GCs) are commonly used anti-inflammatory and immunosuppressive therapeutic agents for a plethora of diseases and conditions. Over 1% of our population receives GC prescriptions annually. Despite the very broad and potent anti-inflammatory effects, prolonged GC therapy can cause serious side effects, including damage to the eye. Between 30-75% of individuals receiving prolonged GC therapy develop GC- induced ocular hypertension (OHT), which if unrecognized can lead to iatrogenic open-angle glaucoma and permanent vision loss. Despite recognition of this significant GC side effect for more than six decades, we still do not understand the reason for differences in susceptibility to GC-induced OHT or the mechanism(s) of action responsible for GC-OHT. We have previously shown that the alternative spliced dominant negative isoform of the glucocorticoid receptor (GRb) inhibits GC activity in cultured human TM cells. TM cells isolated from glaucoma donor eyes (GTM) have low GRb levels and are therefore more sensitive to GCs. Although a number of studies have examined the DEX-induced transcriptome in TM cells and tissues, there is no indication which of the differentially expressed genes or molecular pathways are involved in GC-OHT. Several studies have shown that susceptibility to develop GC-OHT is genetically inherited, but no genes have been definitively linked to GC-OHT. Our overall hypothesis is that GC-OHT is: (a) determined by the ratio of endogenous GRa to GRb expression in the TM; (b) mediated by specific molecular pathways that can be differentiated from GC-responder and non-responder eyes; and (c) genetically determined so that GC-OHT genes can be mapped and identified. This overall hypothesis will be tested in 3 specific aims. Specific Aim #1: Determine the role of endogenous GRb in regulating GC-OHT in human anterior segment ex vivo perfusion culture and in vivo in mice. Specific Aim #2: Determine the TM transcriptome in GC-OHT resistant and sensitive strains of mice and in anterior segment perfusion cultured human eyes in order to identify the molecular pathways that are responsible for GC-OHT. Specific Aim #3: Map and identify the genes responsible for GC-OHT using QTL of the BXD recombinant inbred mouse lines. This research is innovative in that we will evaluate the role of endogenous GRb in mouse strains (with our new mouse model of GC-OHT) and in ex vivo perfusion cultured human anterior segments that differ in sensitivity to GC-OHT, use mouse strains and human perfusion cultured anterior segments that are differentially responsive to GC-OHT to molecularly dissect the pathway responsible for GC-OHT, and map GC-OHT genes using BXD recombinant inbred mice. This work is essential and significant because our experimental results will help determine the role of endogenous GRb in regulating responsiveness to GC-OHT, the molecular mechanisms responsible for GC-OHT, and the best and most effective way to predict steroid responders, which still is an important unmet clinical need as GC-OHT is becoming increasingly prevalent.
糖皮质激素(GCs)是一种常用的抗炎和免疫抑制剂

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Abbot Frederick Clark其他文献

Abbot Frederick Clark的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Abbot Frederick Clark', 18)}}的其他基金

Glucocorticoids, ocular hypertension and glaucoma
糖皮质激素、高眼压症和青光眼
  • 批准号:
    10468972
  • 财政年份:
    2020
  • 资助金额:
    $ 54.04万
  • 项目类别:
Glucocorticoids, ocular hypertension and glaucoma
糖皮质激素、高眼压症和青光眼
  • 批准号:
    10675041
  • 财政年份:
    2020
  • 资助金额:
    $ 54.04万
  • 项目类别:
Glucocorticoids, ocular hypertension and glaucoma
糖皮质激素、高眼压症和青光眼
  • 批准号:
    10056541
  • 财政年份:
    2020
  • 资助金额:
    $ 54.04万
  • 项目类别:
Novel Genome Editing for the Treatment of Glaucoma
用于治疗青光眼的新型基因组编辑
  • 批准号:
    10613463
  • 财政年份:
    2019
  • 资助金额:
    $ 54.04万
  • 项目类别:
Administrative Supplement for Research on Vitamin B3 Dietary Supplements for Eye Disease
维生素B3膳食补充剂治疗眼病研究行政补充
  • 批准号:
    10725441
  • 财政年份:
    2019
  • 资助金额:
    $ 54.04万
  • 项目类别:
Novel Genome Editing for the Treatment of Glaucoma
用于治疗青光眼的新型基因组编辑
  • 批准号:
    9765843
  • 财政年份:
    2019
  • 资助金额:
    $ 54.04万
  • 项目类别:
Novel Genome Editing for the Treatment of Glaucoma
用于治疗青光眼的新型基因组编辑
  • 批准号:
    10393523
  • 财政年份:
    2019
  • 资助金额:
    $ 54.04万
  • 项目类别:
Conditionally immortalized TM cell and RGC lines from Animal Model
来自动物模型的条件永生化 TM 细胞和 RGC 系
  • 批准号:
    8636379
  • 财政年份:
    2014
  • 资助金额:
    $ 54.04万
  • 项目类别:
Novel Glaucoma Treatment Using Genome Editing
使用基因组编辑的新型青光眼治疗
  • 批准号:
    9254557
  • 财政年份:
    2014
  • 资助金额:
    $ 54.04万
  • 项目类别:
Novel Glaucoma Treatment Using Genome Editing
使用基因组编辑的新型青光眼治疗
  • 批准号:
    9039605
  • 财政年份:
    2014
  • 资助金额:
    $ 54.04万
  • 项目类别:

相似海外基金

Impact of tissue resident memory T cells on the neuro-immune pathophysiology of anterior eye disease
组织驻留记忆 T 细胞对前眼疾病神经免疫病理生理学的影响
  • 批准号:
    10556857
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
Fear and anxiety circuit mechanisms in anterior hypothalamic nucleus
下丘脑前核的恐惧和焦虑环路机制
  • 批准号:
    10789153
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
Elucidating signaling networks in Anterior Segment development, repair and diseases
阐明眼前节发育、修复和疾病中的信号网络
  • 批准号:
    10718122
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
The Intimate Interplay Between Keratoconus, Sex Hormones, and the Anterior Pituitary
圆锥角膜、性激素和垂体前叶之间的密切相互作用
  • 批准号:
    10746247
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
Anterior Insula Projections for Alcohol Drinking/Anxiety Interactions in Female and Male Rats
雌性和雄性大鼠饮酒/焦虑相互作用的前岛叶预测
  • 批准号:
    10608759
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
Impact of tissue resident memory T cells on the neuro-immunepathophysiology of anterior eye disease
组织驻留记忆 T 细胞对前眼疾病神经免疫病理生理学的影响
  • 批准号:
    10804810
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
Investigation of the effect of anterior eye shape on myopia progression due to prolonged near work.
研究因长时间近距离工作而导致的前眼形状对近视进展的影响。
  • 批准号:
    23K09063
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation and characterization of anterior pituitary stem cells from human pluripotent stem cells
人多能干细胞垂体前叶干细胞的产生和表征
  • 批准号:
    23K08005
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
EASI-TOC: Endovascular Acute Stroke Intervention-Tandem OCclusion: atrial of acute cervical internal carotid artery stenting during endovascularthrombectomy for anterior circulation stroke
EASI-TOC:血管内急性卒中干预-串联闭塞:前循环卒中血管内血栓切除术期间急性颈内动脉心房支架置入术
  • 批准号:
    490056
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
    Operating Grants
Anterior cruciate ligament injury: towards a gendered environmental approach
前十字韧带损伤:走向性别环境方法
  • 批准号:
    485090
  • 财政年份:
    2023
  • 资助金额:
    $ 54.04万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了